Report overview
Histoplasmosis is an infection that occurs from breathing spores of a fungus called Histoplasma capsulatum. Histoplasmosis is a fungal infection that occurs throughout the world. Histoplasma fungus grows as a mold in the soil. The soil that contains the droppings of bat or birds usually contains large amount of this fungus. The people with weakened immune system are usually more prone and increases the risk of being affected or reactivated with histoplasmosis. Usually people very young, old people and people affected with cancer, AIDS or organ transplant have severe symptoms. The people with chronic lung disease such as bronchiectasis or emphysema have high risk of severe pain. The common symptoms of histoplasmosis is fever, chills, cough, chest pain, red skin bumps, mouth sores etc. In some patients suffering from histoplasmosis may spread throughout the body and cause irritation and swelling in response to infection.
This report contains market size and forecasts of Histoplasmosis Treatment in Global, including the following market information:
Global Histoplasmosis Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Histoplasmosis Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Amphotericin B Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Histoplasmosis Treatment include Bristol Myers Squibb, Sigma tau pharmaceuticals Inc., Three rivers pharmaceuticals, Astellas pharma US Inc., Abbott laboratories, Abraxis pharmaceutical products, Teva parenteral medicines Inc. and X gen pharmaceuticals Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Histoplasmosis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Histoplasmosis Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Histoplasmosis Treatment Market Segment Percentages, by Type, 2021 (%)
Amphotericin B
Itraconazole
Ketoconazole
Other
Global Histoplasmosis Treatment Market, by Distribution Channel, 2017-2022, 2023-2028 ($ millions)
Global Histoplasmosis Treatment Market Segment Percentages, by Distribution Channel, 2021 (%)
Hospitals Pharmacies
Drug stores and retail pharmacy
E-commerce
Other
Global Histoplasmosis Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Histoplasmosis Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Histoplasmosis Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Histoplasmosis Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol Myers Squibb
Sigma tau pharmaceuticals Inc.
Three rivers pharmaceuticals
Astellas pharma US Inc.
Abbott laboratories
Abraxis pharmaceutical products
Teva parenteral medicines Inc.
X gen pharmaceuticals Inc.
